Overview Quote
Stock Activity
| Day Low - High | 6.02 - 6.48 |
| 52wk Low - High | 3.10 - 7.73 |
| Previous Close | 6.19 |
| Avg. Volume | 774,010 |
| Industry | MED-BIOMED/GENE |
| Market Cap | 573.19 M |
| Div - Yield | 0.00 - 0.00 |
| Beta | 1.94 |
| PE (Forward) | 0.00 |
| Current Year Est. | -0.78 |
| Quarterly Earnings ESP |
0.00% |
Premium research
Zacks Rank
|
3 |
Zacks Recommendation
|
Neutral |
Zacks Industry Rank
|
95 out of 265 |
Equity Research Report
|
PREMIUM |
( = Change in last 30 days)
Get all our stock ratings and recommendations with a Free Trial to Zacks Premium Start Free Trial
Company Description
OREXIGEN THERAPEUTICS, INC. is a biopharmaceutical company focused on the development of pharmaceutical product candidates for the treatment of central nervous system disorders, including obesity. The Company's lead combination product candidates targeted for obesity are Contrave, which is in Phase III clinical trials, and Empatic, which is in the later stages of Phase II clinical development. Both product candidates are designed to take advantage of the Company's understanding of how the brain appears to regulate appetite and energy expenditure, as well as the mechanisms that come into play to limit weight loss over time. Each product candidate is designed to act on a specific group of neurons in the central nervous system with the goal of achieving appetite suppression and sustained weight loss.
NYSE data is at least 20 minutes delayed.
NASDAQ data is at least 15 minutes delayed.
Earnings Estimates
| Current Qtr (06/2013) |
Next Qtr (09/2013) |
Current Year (12/2013) |
Next Year (12/2014) |
|
|---|---|---|---|---|
| Average Estimate | -0.19 | -0.17 | -0.78 | -0.24 |
| Number of Estimates | 4 | 3 | 5 | 4 |
| Low Estimate | -0.20 | -0.19 | -0.83 | -0.80 |
| High Estimate | -0.17 | -0.14 | -0.68 | NA |
| Year Ago EPS | -0.25 | -0.44 | -1.27 | -0.78 |
| EPS Growth | 25.00% | 60.61% | 38.27% | 69.71% |
Industry Analysis
| Name | Symbol | Previous Close | Zacks Rank | Zacks Recommendation |
|---|---|---|---|---|
| OREXIGEN THERAP | OREX | 6.19 | ![]() |
![]() |
| AETERNA ZENTARS | AEZS | 2.06 | ![]() |
![]() |
| ANIKA THERAPEUT | ANIK | 13.75 | ![]() |
![]() |
| GENTIUM SPA-ADR | GENT | 8.79 | ![]() |
![]() |
| AASTROM BIOSCI | ASTM | 0.57 | ![]() |
![]() |
| ACADIA PHARMA | ACAD | 13.42 | ![]() |
![]() |
| ACHILLION PHARM | ACHN | 7.74 | ![]() |
![]() |
| ADDEX THERA LTD | ADDXF | 6.62 | ![]() |
![]() |
| AFFYMAX INC | AFFY | 1.40 | ![]() |
![]() |
| ALEXION PHARMA | ALXN | 100.57 | ![]() |
![]() |
Sector:Medical>> Industry:MED-BIOMED/GENE
Zacks Commentary
ARNA Sheds Light on Belviq Launch
May 09, 2013
VIVUS Reports Wider Loss
May 09, 2013
The Zacks Analyst Blog Highlights: Microsoft, VIVUS, Arena Pharmaceuticals, Orexigen Therapeutics and UCB
Apr 19, 2013
Expanded Access for VIVUS' Qsymia
Apr 18, 2013
ARNA/Eisai's Belviq Filed in Mexico
Apr 03, 2013
Vivus Opts for Royalty Financing
Apr 02, 2013
Company News for March 15, 2013
Mar 15, 2013
Loss at OREX Narrower than Expected
Mar 14, 2013
Financials
| EPS TTM | -1.31 |
| Sales | 3 |
| Net Income | -99 |
| Price/Earnings | NA |
| Price/Book | 9.78 |
| Price/Cash Flow | NA |
| Price/Sales | 167.21 |
News
5 Stocks Under $10 Set to Soar - TheStreet.com
May 23, 2013
Buyers Accumulate Shares of Orexigen Therapeutics, Up 2.3% - Financial News Network Online - Market Movers
May 23, 2013
Why This Obesity Drug Is the Sector`s Best Bet - TheMotleyFool
May 23, 2013
3 Pipeline Obesity Treatments You Should Watch - TheMotleyFool
May 22, 2013
Orexigen Therapeutics Q1 net loss increases - Datamonitor
May 21, 2013
Orexigen Therapeutics to Present at the UBS Healthcare Conference - Close-Up Media
May 21, 2013
Orexigen Therapeutics Earnings Review: 12 Days after Announcement Shares Up 0.7% (OREX) - Comtex Smartrend(R)
May 20, 2013
Shares of Orexigen Therapeutics Receive a Boost, Up 1.5% - Financial News Network Online - Market Movers
May 20, 2013
Broker Recommendations
| Current ABR | 1.57 |
| ABR (Last Week) | 1.57 |
| # of recs in ABR | 7 |
| Average Target Price | 10.50 |
| Industry Rank by ABR | 95 out of 265 |
| Rank in Industry | 36 out of 152 |

3